The S&P 500 Index ($SPX ) (SPY ) closed down -0.51% on Monday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.39%.  December E-mini S&P futures (ESZ26 ) fell -0.49%, and December E-mini Nasdaq futures...

Broader Market Settles Lower on Weakness in Chipmakers and AI Stocks

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Tempus AI Inc (Symbol: TEM), where a total of 53,942 contracts have traded so far, representing approximately 5.4 million underlying shares.  That amounts to about 83.8%

Noteworthy Monday Option Activity: TEM, RIVN, NRG

(RTTNews) - Tempus AI, Inc. (TEM), a technology company focused on applying artificial intelligence to precision medicine, reported third-quarter 2026 financial results on Monday, with revenue rising 23% year over year.

Tempus Raises FY26 Revenue Guidance After Q3 Revenue Growth Of 23%; Stock Up 

The S&P 500 Index ($SPX ) (SPY ) is up +0.74% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.74%.  December E-mini S&P futures (ESZ26 ) are up +0.72%, and December E-mini Nasdaq futures...

Stocks Rally as Crude Oil Sinks on US-Iran Hopes

The S&P 500 Index ($SPX ) (SPY ) is up +0.62% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.69%.  December E-mini S&P futures (ESZ26 ) are up +0.58%, and December E-mini Nasdaq futures...

Stocks Rebound as Chipmakers Recover and Crude Oil Plunges

(RTTNews) - Below are the earnings highlights for Tempus AI Inc (TEM):

Tempus AI Inc Q3 Earnings Summary 

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Tempus AI, Inc. News